Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation
PHASE3CompletedINTERVENTIONAL
Enrollment
973
Participants
Timeline
Start Date
March 31, 2001
Study Completion Date
July 31, 2002
Conditions
Alzheimer DiseaseDementia
Interventions
DRUG
galantamine hydrobromide
All Listed Sponsors
lead
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY
NCT00253214 - Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation | Biotech Hunter | Biotech Hunter